Diagnostic Characterization and Evolution of Triple Negative Thrombocytosis (CASTETTE)

Diagnostic Characterization and Evolution of Triple Negative Thrombocytosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06481332

Acronym

CASTETTE

Enrollment

300

Registered

2024-07-01

Start date

2024-06-25

Completion date

2024-12-31

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloproliferative Neoplasm

Brief summary

Evaluation of Event free survival in patients with triple-negative thrombocytosis

Detailed description

Patients with non-reactive thrombocytosis, explored at least by bone marrow biopsy and NGS panel will be included. Clinical and biological characteristics as well as evolution will be recorded retrospectively.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients with non reactive thrombocytosis for at least 6 months * availability of bone marrow biopsy and NGS panel

Exclusion criteria

* Unable to consent

Design outcomes

Primary

Measure	Time frame
Event-free survival	3 years

Countries

France

Outcome results